Literature DB >> 24066839

The burden of preserved ejection fraction heart failure in a real-world Swedish patient population.

Jan Stålhammar1, Lee Stern, Ragnar Linder, Steve Sherman, Rohan Parikh, Rinat Ariely, Celine Deschaseaux, Gerhard Wikström.   

Abstract

OBJECTIVES: To evaluate resource use and associated costs in patients with a diagnosis of heart failure with preserved ejection fraction (HF-PEF) in Sweden.
METHODS: This retrospective study identified real-world patients with an ICD-10 diagnosis code for heart failure (I50) for the period between July 1, 2005 and December 31, 2006 from electronic medical records of primary care centers in Uppsala County Council, and in the Swedish patient registry data. Patients were categorized as having HF-PEF (left ventricle ejection fraction [LVEF] > 50%) during the index period. The study assessed medication utilization, outpatient visits, hospitalizations, and associated healthcare costs, as well as the incidence rates and time to all-cause and heart failure mortality following the index period.
RESULTS: The study included 137 HF-PEF patients with a mean age of 77.1 (SD = 9.1) years. Over 50% of HF-PEF patients were female and hypertensive. Nearly all patients received ≥ 1 medication post-index. Patients had an average of 1.5 heart failure related hospitalizations per follow-up year. The average annual per patient cost for the management of a HF-PEF patient was found in Sweden to be Swedish Krona (SEK) 108,246 (EURO [EUR] 11,344). Hospitalizations contributed to more than 80% of the total cost. All-cause mortality over the 18-month study period was 25.5%, and more than 50% of these deaths occurred within 1 year of index. LIMITATIONS: Due to the limitations of registry data, it is not possible to confirm the HF diagnosis, and therefore the accuracy of registry records must be assumed. Other factors such as short follow-up time, the study-mandated LVEF assessment, and a lack of drug duration data may also have an impact on the study results.
CONCLUSIONS: All-cause mortality was high in the HF-PEF population, with more than half of patients dying within 1 year of study follow-up. Study results also indicate that 60% of HF-PEF patients have ≥ 1 hospitalization during follow-up. Hospitalizations, especially heart failure related admissions, represent a substantial proportion of the total healthcare burden of patients with HF-PEF in Sweden.

Entities:  

Mesh:

Year:  2013        PMID: 24066839     DOI: 10.3111/13696998.2013.848808

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  5 in total

1.  A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective.

Authors:  Steve Ryder; Kathleen Fox; Pratik Rane; Nigel Armstrong; Ching-Yun Wei; Sohan Deshpande; Lisa Stirk; Yi Qian; Jos Kleijnen
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

2.  Systematic review of economic burden of heart failure.

Authors:  Asrul Akmal Shafie; Yui Ping Tan; Chin Hui Ng
Journal:  Heart Fail Rev       Date:  2018-01       Impact factor: 4.214

Review 3.  Hospitalisation costs associated with heart failure with preserved ejection fraction (HFpEF): a systematic review.

Authors:  Hannah Clark; Rezwanul Rana; Jeff Gow; Melissa Pearson; Tom van der Touw; Neil Smart
Journal:  Heart Fail Rev       Date:  2021-03-25       Impact factor: 4.214

4.  Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China.

Authors:  Yaohui Jiang; Jun Xie
Journal:  Front Cardiovasc Med       Date:  2022-09-02

5.  Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis.

Authors:  Nicholas R Jones; Andrea K Roalfe; Ibiye Adoki; F D Richard Hobbs; Clare J Taylor
Journal:  Eur J Heart Fail       Date:  2019-09-16       Impact factor: 15.534

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.